3. Development trend of clinical immunotherapy based on DC and T cells
Currently, immune checkpoint inhibitors have been widely used in clinical cancer treatments and are an important treatment for advanced NSCLC. CAR-T has emerged as a genuine modality for treating blood tumors. However, their low efficacy in treating solid tumors limits their application. Although it has been reported, it is still in the exploratory stage [103-104]. In combination with the clinical application of immunotherapy and advances made in understanding immune cells, especially DC, the trend of next-generation immunotherapy is moving towards developing artificial DC and CAR-T that can be used to treat solid tumors. Both can override the limitation of low immunity in tumor patients.